{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C+Relapsed&page=23", "query": { "condition": "Non-Hodgkin's Lymphoma, Relapsed", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 821, "total_pages": 83, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C+Relapsed&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C+Relapsed&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T00:32:14.123Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01351935", "title": "Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Cell Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "AVL-292", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2011-07-18", "completion_date": "2015-06-26", "has_results": false, "last_update_posted_date": "2019-11-08", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 13, "location_summary": "Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351935" }, { "nct_id": "NCT01197560", "title": "Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2010-09-02", "completion_date": "2018-04-05", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 13, "location_summary": "Burbank, California • Orlando, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01197560" }, { "nct_id": "NCT00551239", "title": "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "pixantrone dimaleate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "2007-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551239" }, { "nct_id": "NCT02226965", "title": "PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Diffuse Large B-Cell" ], "interventions": [ { "name": "PNT2258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-12", "completion_date": "2018-08-22", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 26, "location_summary": "Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Winter Haven", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226965" }, { "nct_id": "NCT02240719", "title": "Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "bendamustine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2014-10", "completion_date": "2018-04-09", "has_results": false, "last_update_posted_date": "2019-01-04", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02240719" }, { "nct_id": "NCT02961881", "title": "A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-09-18", "completion_date": "2021-09-02", "has_results": true, "last_update_posted_date": "2024-02-02", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 3, "location_summary": "Duarte, California • Chicago, Illinois • Hackensack, New Jersey", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02961881" }, { "nct_id": "NCT05283720", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride [HCl]", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "CC-99282", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 264, "start_date": "2022-06-14", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 18, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283720" }, { "nct_id": "NCT06484920", "title": "A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "B-cell Lymphoma" ], "interventions": [ { "name": "ATRA", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rita Assi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-11-18", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 2, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06484920" }, { "nct_id": "NCT00098566", "title": "Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma", "Quality of Life" ], "interventions": [], "intervention_types": [], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2002-12", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098566" }, { "nct_id": "NCT06839456", "title": "Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "High Risk Acute Lymphoblastic Leukemia", "High Risk Acute Myeloid Leukemia", "Relapse Leukemia", "MDS (Myelodysplastic Syndrome)", "Relapsed Non-Hodgkin Lymphoma", "Acquired Aplastic Anemia", "Inherited BMF Syndrome", "Immunodeficiency", "Primary Immune Regulatory Disorder", "Hemoglobinopathies", "Bone Marrow Failure", "Inborn Errors of Metabolism", "HLH" ], "interventions": [ { "name": "Phase 1 Dose Level 1", "type": "DEVICE" }, { "name": "Phase 1 Dose Level 2", "type": "DEVICE" }, { "name": "Phase 1 Dose Level 3", "type": "DEVICE" }, { "name": "Phase 2 Maximum Tolerated Dose determined in Phase 1", "type": "DEVICE" }, { "name": "Phase 2 Established Dose from prior study, NCT03810196", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Month to 25 Years" }, "enrollment_count": 100, "start_date": "2025-03-21", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-15T00:32:14.123Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06839456" } ] }